BioNotebook: Seragon, Arcturus, Seattle Genetics, Cytos, CIRM
This article was originally published in Scrip
Seragon announces Series A funding amount; Arcturus raises $5m Series A; Seattle Genetics enters clinic with new ADC; Cytos earns Phase IIb cash; and CIRM president steps down.
You may also be interested in...
Emerging Company Profile: San Diego-based Arcturus Therapeutics has developed technology for the targeted delivery of RNA therapeutics, which Johnson & Johnson's Janssen subsidiary will evaluate for the first time in humans in a clinical trial starting as early as this year for the partners' hepatitis B drug candidate.
Good news in the biopharma industry and the US economy gave public drug developers the boost they needed to raise cash, including Karuna’s $750m offering. Private company financings slowed during the second week of August, but Prellis and Vector BioPharma raised venture capital.
CEO John Glasspool spoke with Scrip about why Anthos believes it has a good shot against big competitors in a market that is expected to generate blockbuster sales across multiple products.